Literature DB >> 23525736

Regional differences in healthcare delivery for gastroparesis.

Klaus Bielefeldt1.   

Abstract

AIM: Few studies have examined the effects of various interventions in gastroparesis. The goal of the present study was to determine whether inpatient management and outcomes differed among states across the United States.
METHODS: Using population statistics and the State Inpatient Database (Agency for Healthcare Research and Quality), regional differences in admissions for gastroparesis, inpatient mortality, length of stay, nursing home transfers, and rates of endoscopy, gastrostomy placement, and nutritional support were assessed.
RESULTS: Admissions for gastroparesis ranged from 24.3 ± 0.8/100,000 in Utah to 117.1 ± 9.7/100,000 in Maryland, with mortality rates similarly varying fourfold from 0.5 ± 0.1/100,000 in Colorado to 2.3 ± 0.1/100,000 in Florida. Intervention rates differed between states (endoscopy: 6.8 ± 0.8 % in Wyoming versus 23.1 ± 0.4 % in Florida; gastrostomy: 0.8 ± 0.1 % in North Carolina versus 3.3 ± 0.8 % in Hawaii; nutritional support: 1.2 ± 0.2 % in West Virginia versus 7.0 ± 0.6 % in New Jersey). Admissions rates were independently predicted by high overall hospitalizations within a state. Higher population density, median incomes and admissions to for-profit hospitals correlated with endoscopy rates. Coexisting heart failure and male gender were associated with higher likelihood of gastrostomy placement, while initiation of nutritional support was predicted by physician supply and insurance status. Age cohort, Medicare coverage, poverty rates and endoscopic testing independently predicted mortality, while length of stay correlated with diagnostic and therapeutic interventions.
CONCLUSIONS: There is a significant variability in admissions, interventions and outcomes for gastroparesis. While biological factors, such as comorbidities and age, contribute to this variability, the data suggest that socioeconomic variables significantly affect approaches to gastroparesis treatment in the United States.

Entities:  

Mesh:

Year:  2013        PMID: 23525736     DOI: 10.1007/s10620-013-2643-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  48 in total

1.  Diabetic gastroparesis improved by percutaneous endoscopic jejunostomy.

Authors:  D Devendra; B A Millward; S P Travis
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

2.  Physicians can boost shrinking revenues with in-house ancillary services.

Authors: 
Journal:  Perform Improv Advis       Date:  2004-04

3.  Abdominal pain is a frequent symptom of gastroparesis.

Authors:  Dinu Cherian; Priyanka Sachdeva; Robert S Fisher; Henry P Parkman
Journal:  Clin Gastroenterol Hepatol       Date:  2010-06-01       Impact factor: 11.382

4.  Pain: the overlooked symptom in gastroparesis.

Authors:  W A Hoogerwerf; P J Pasricha; A N Kalloo; M M Schuster
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

Review 5.  Reflux and sex: what drives testing, what drives treatment?

Authors:  Salman Nusrat; Sanober Nusrat; Klaus Bielefeldt
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 2.566

6.  Racial and ethnic trends of colorectal cancer screening among Medicare enrollees.

Authors:  Chyke A Doubeni; Adeyinka O Laiyemo; Carrie N Klabunde; Angela C Young; Terry S Field; Robert H Fletcher
Journal:  Am J Prev Med       Date:  2010-02       Impact factor: 5.043

7.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

8.  Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review.

Authors:  R J Fontana; J L Barnett
Journal:  Am J Gastroenterol       Date:  1996-10       Impact factor: 10.864

9.  Regional differences in EpiPen prescriptions in the United States: the potential role of vitamin D.

Authors:  Carlos A Camargo; Sunday Clark; Michael S Kaplan; Philip Lieberman; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2007-06-07       Impact factor: 10.793

10.  GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting.

Authors:  Rachel Halpern; Smita Kothari; Mahesh Fuldeore; Victoria Zarotsky; Victoria Porter; Omar Dabbous; Jay L Goldstein
Journal:  Dig Dis Sci       Date:  2009-08-21       Impact factor: 3.199

View more
  6 in total

1.  Time trends in gastroparesis treatment.

Authors:  Anwar Dudekula; Shiraz Rahim; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2014-09-26       Impact factor: 3.199

2.  Diagnostic stringency and healthcare needs in patients with biliary dyskinesia.

Authors:  Nitin Aggarwal; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2013-08-11       Impact factor: 3.199

Review 3.  Gastroparesis.

Authors:  Michael Camilleri; Victor Chedid; Alexander C Ford; Ken Haruma; Michael Horowitz; Karen L Jones; Phillip A Low; Seon-Young Park; Henry P Parkman; Vincenzo Stanghellini
Journal:  Nat Rev Dis Primers       Date:  2018-11-01       Impact factor: 52.329

4.  In-hospital mortality in gastroparesis population and its predictors: A United States-based population study.

Authors:  Saad Saleem; Faisal Inayat; Muhammad Aziz; Eric O Then; Yousaf Zafar; Vinaya Gaduputi
Journal:  JGH Open       Date:  2021-01-27

5.  Healthcare utilization and costs associated with gastroparesis.

Authors:  Vaibhav Wadhwa; Dhruv Mehta; Yash Jobanputra; Rocio Lopez; Prashanthi N Thota; Madhusudhan R Sanaka
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

6.  United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.

Authors:  Jolien Schol; Lucas Wauters; Ram Dickman; Vasile Drug; Agata Mulak; Jordi Serra; Paul Enck; Jan Tack
Journal:  United European Gastroenterol J       Date:  2021-04       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.